Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
4651529
Author(s)
de Vries, L. E.; Jansen, P. A. M.; Barcelo, C.; Munro, J.; Verhoef, J. M. J.; Pasaje, C. F. A.; Rubiano, K.; Striepen, J.; Abla, N.; Berning, L.; Bolscher, J. M.; Demarta-Gatsi, C.; Henderson, R. W. M.; Huijs, T.; Koolen, K. M. J.; Tumwebaze, P. K.; Yeo, T.; Aguiar, A. C. C.; Angulo-Barturen, I.; Churchyard, A.; Baum, J.; Fernandez, B. C.; Fuchs, A.; Gamo, F. J.; Guido, R. V. C.; Jimenez-Diaz, M. B.; Pereira, D. B.; Rochford, R.; Roesch, C.; Sanz, L. M.; Trevitt, G.; Witkowski, B.; Wittlin, S.; Cooper, R. A.; Rosenthal, P. J.; Sauerwein, R. W.; Schalkwijk, J.; Hermkens, P. H. H.; Bonnert, R. V.; Campo, B.; Fidock, D. A.; Llinas, M.; Niles, J. C.; Kooij, T. W. A.; Dechering, K. J.
Animals; Antimalarials, therapeutic use; Folic Acid Antagonists; Malaria, drug therapy; Malaria, Falciparum, drug therapy; Malaria, Vivax, drug therapy; Mice; Pantothenic Acid, analogs & derivatives; Plasmodium falciparum, genetics; Rats
Abstract
Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our studies demonstrate attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection. The compound shows single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocks P. falciparum transmission to Anopheles mosquitoes. Genetic and biochemical studies identify AcAS as the target of the MMV693183-derived antimetabolite, CoA-MMV693183. Pharmacokinetic-pharmacodynamic modelling predict that a single 30 mg oral dose is sufficient to cure a malaria infection in humans. Toxicology studies in rats indicate a > 30-fold safety margin in relation to the predicted human efficacious exposure. In conclusion, MMV693183 represents a promising candidate for further (pre)clinical development with a novel mode of action for treatment of malaria and blocking transmission.
